The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Assessing high-risk AML
Nigel Russell
• 15 Jun 2020
Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, explores how high-risk acute myeloid leukemia (AML) can be identified as well as the importance of genomic profiling and minimal residual disease (MRD) in AML assessment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
